Experimental study demonstrates rhodium(II)-catalyzed divergent dearomative cyclization of 1,3-azoles with cyclopropenes, highlighting scalable access to distinct bioactive nitrogen heterocycles.
Herein, we report a rhodium(II)-catalyzed divergent dearomative cyclization of benzimidazoles and benzoxazoles with cyclopropenes that proceeds through a unified azolium ylide mechanism. Scaffold tuning of the 1,3-azole substrates enables two distinct pathways: pyrroloimidazoles from benzimidazoles and benzoxazoloazepines from benzoxazoles. This method features good functional group tolerance and gram-scale scalability, providing straightforward access to two classes of pharmaceutically relevant nitrogen heterocycles.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: